Some Quick Facts About Gilead Sciences (GILD)

After moving 1.3% during today's evening session, Gilead Sciences is now trading at a price of $81.23 per share. On average, analysts give it a target price of $85.47.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Potential Gilead Sciences Investors Should Analyze the Following:

  • Gilead Sciences has moved 4.0% over the last year.

  • The company has a price to earnings growth (PEG) ratio of 3.05. A number between 0 and 1 could mean that the market is undervaluing Gilead Sciences's estimated growth potential

  • Its Price to Book (P/B) ratio is 4.79

  • Gilead Sciences currently returns an annual dividend yield of 3.7%.

Understanding Gilead Sciences's Operating Margins

Date Reported Total Revenue ($ k) Operating Expenses ($ k) Operating Margins (%)
2023 27,382,000 18,908,000 31
2022 27,281,000 19,951,000 27
2021 27,305,000 17,387,000 36
2020 24,689,000 20,618,000 16
2019 nan 18,162,000
2018 nan 13,927,000

None None

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.